This content is in French.
Migraine and glaucoma: CGRP inhibitors may also protect vision
18 mai 2026
By Elodie Vaz | Published on May 18,
2026 | 4 min read
Glaucoma is one of the leading causes of irreversible blindness worldwide. This progressive optic neuropathy, characterized by damage to the optic nerve often linked to elevated intraocular pressure, still raises many questions about its underlying pathophysiological mechanisms. Among the avenues being explored is the role of cerebral and ocular blood flow, which has already been implicated in another common neurological disorder: migraine.
A study published on May 6, 2026 by the American Academy of Neurology in the journal Neurology now suggests that a recent class of preventive migraine treatments, calcitonin gene-related peptide (CGRP) inhibitors, may be associated with a reduced risk of glaucoma.
Glaucoma is one of the leading causes of irreversible blindness worldwide. This progressive optic neuropathy, characterized by damage to the optic nerve often linked to elevated intraocular pressure, still raises many questions about its underlying pathophysiological mechanisms. Among the avenues being explored is the role of cerebral and ocular blood flow, which has already been implicated in another common neurological disorder: migraine.
A study published on May 6, 2026 by the American Academy of Neurology in the journal Neurology now suggests that a recent class of preventive migraine treatments, calcitonin gene-related peptide (CGRP) inhibitors, may be associated with a reduced risk of glaucoma.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Glaucoma Risk Associated With Calcitonin Gene–Related Peptide Inhibitor Use in Migraine
View the source
